We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
(-30%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
266.32%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
Baxter International
BAX
|
+$3.81M |
| 3 |
Akebia Therapeutics
AKBA
|
+$2.87M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.46M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$1.81M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
+$8.82M |
| 2 |
CELG
Celgene Corp
CELG
|
+$6.57M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$6.35M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$5.44M |
| 5 |
Viatris
VTRS
|
+$2.57M |
Sector Composition
| 1 | Healthcare | 48.43% |
| 2 | Technology | 4.06% |
| 3 | Consumer Discretionary | 2.5% |
| 4 | Consumer Staples | 1.74% |
| 5 | Materials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$70.9B
| $12M | 12.52% |
33,159
+25,769
| +349% | +$10.6M |
|
|
2
PUT
Regeneron Pharmaceuticals
REGN
$70.9B
| $6.81M | 7.14% |
48,500
-17,800
| -27% | -$7.33M |
|
3
Abbott
ABT
$175B
| $5.66M | 5.93% |
135,300
+13,000
| +11% | +$515K |
|
|
4
Baxter International
BAX
$11.7B
| $4.11M | 4.3% |
+100,000
| New | +$3.81M |
|
|
5
Akebia Therapeutics
AKBA
$359M
| $3.51M | 3.68% |
389,919
+353,763
| +978% | +$2.87M |
|
|
6
Gilead Sciences
GILD
$167B
| $2.52M | 2.64% |
27,390
-97,843
| -78% | -$8.82M |
|
|
OTIC
7
DELISTED
Otonomy, Inc.
OTIC
| $2.33M | 2.44% |
+156,437
| New | +$2.46M |
|
|
ICPT
8
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2M | 2.1% |
12,900
-500
| -4% | -$59K |
|
|
ICPT
9
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.97M | 2.06% |
+15,314
| New | +$1.81M |
|
10
PUT
Bausch Health
BHC
$1.8B
| $1.9M | 1.99% |
135,100
+46,400
| +52% | +$3.43M |
|
|
ALR
11
DELISTED
Alere Inc
ALR
| $1.83M | 1.92% |
+36,163
| New | +$1.73M |
|
|
MDVN
12
DELISTED
MEDIVATION, INC.
MDVN
| $1.75M | 1.84% |
+38,155
| New | +$1.38M |
|
13
IBM
IBM
$200B
| $1.52M | 1.59% |
10,473
-3,787
| -27% | -$484K |
|
|
CMRX
14
DELISTED
Chimerix, Inc.
CMRX
| $1.47M | 1.54% |
287,712
+133,612
| +87% | +$872K |
|
|
15
PUT
Baxter International
BAX
$11.7B
| $1.42M | 1.49% |
+100,000
| New | +$3.81M |
|
|
CASC
16
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $1.29M | 1.35% |
169,268
+119,266
| +239% | +$918K |
|
17
Rocket Pharmaceuticals
RCKT
$376M
| $1.25M | 1.31% |
42,388
+35,783
| +542% | +$1.07M |
|
18
Humana
HUM
$48B
| $1.2M | 1.26% |
6,578
-9,357
| -59% | -$1.62M |
|
19
Cal-Maine
CALM
$4.2B
| $1.19M | 1.24% |
22,892
-6,162
| -21% | -$308K |
|
|
LUMO
20
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.16M | 1.22% |
2,222
-5,756
| -72% | -$1.17M |
|
|
POT
21
DELISTED
Potash Corp Of Saskatchewan
POT
| $1.02M | 1.07% |
60,000
-40,000
| -40% | -$673K |
|
|
22
Chipotle Mexican Grill
CMG
$44.2B
| $930K | 0.97% |
98,700
-571,950
| -85% | -$5.44M |
|
23
Expedia Group
EXPE
$32.3B
| $914K | 0.96% |
+8,481
| New | +$904K |
|
|
TWC
24
DELISTED
TIME WARNER CABLE INC NEW COM STK
TWC
| $849K | 0.89% |
+4,151
| New | +$785K |
|
|
ADT
25
DELISTED
ADT Corp
ADT
| $806K | 0.84% |
+19,541
| New | +$686K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2016 Portfolio in Review
As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.
- FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
- FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
- FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
- FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
- FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
- FT Options opened 183 new positions and closed 99 in Q1 2016.
- FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.
Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.